Experience

Davis Polk advised the sole book-running manager in an SEC-registered offering by Amerant Bancorp Inc. of $60 million aggregate principal amount of 5.750% notes due 2025. The notes are…

Davis Polk advised the initial purchaser in connection with a Rule 144A offering by CryoLife, Inc. of $100 million aggregate principal amount of its 4.250% convertible senior notes due 2025…

Davis Polk achieved a significant victory this week for its client, the New York Stock Exchange (“NYSE”), in a dispute between the three largest U.S. stock-exchange groups and the…

Davis Polk advised the joint book-running managers on an SEC-registered offering by General Motors Financial Company, Inc. of its $1.25 billion aggregate principal amount of 2.750% senior…

Davis Polk advised Genetron Holdings Limited on its SEC-registered initial public offering of 16,000,000 American Depositary Shares. Each ADS represents five ordinary shares. Genetron has…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $124.7 million SEC-registered offering of 28,503,220 shares of…

Davis Polk advised Uniti Group Inc., as issuer, in connection with a new SEC-registered at-the-market offering program by Uniti under which Uniti may issue and sell shares of its common…

Davis Polk advised Equinix, Inc. on an SEC-registered offering of $2.6 billion aggregate principal amount of senior notes. The offering consisted of $500 million aggregate principal amount…

Davis Polk advised the dealers in connection with the offering by Danske Bank of $1.25 billion aggregate principal amount of 1.226% preferred senior callable notes due 2024. Danske…

Davis Polk advised the underwriters in connection with a public offering of 6,666,667 shares of common stock of IDEAYA Biosciences, Inc. at $15.00 per share, for total gross proceeds of …